Dextromethorphan abuse among opioid-dependent patients by Windhab, Laura G et al.








Dextromethorphan abuse among opioid-dependent patients
Windhab, Laura G ; Gastberger, Salome ; Hulka, Lea M ; Baumgartner, Markus R ; Soyka, Michael ;
Müller, Thomas J ; Seifritz, Erich ; Mutschler, Jochen
Abstract: Background: Among opioid-dependent patients on maintenance therapy, concomitant drug
abuse is a serious problem. Dextromethorphan, an over-the-counter antitussive agent that can be pur-
chased without prescription, is a drug with a high potential for misuse, especially when consumed in
high doses.The objective of this study was to investigate possible abuse of dextromethorphan among
substituted opioid-dependent patients and comparison of subjective and objective findings.Due to its
ability to increase serotonin levels, opioid-dependent patients may be particularly susceptible to dex-
tromethorphan misuse. Dextromethorphan misuse may have side effects, including psychiatric symptoms
and serotonin syndrome, and may induce assault, suicide, or homicide. Methods: A total of 104 opioid-
dependent patients in maintenance treatment were included in this cross-sectional study conducted in
the outpatient department of the Psychiatric Hospital, University of Zurich. Study participants were
divided into 2 groups based on laboratory results: dextromethorphan abusers (n = 12) and nonabusers
(n = 92). The objective use and concentrations of dextromethorphan was detected using 3-month hair
toxicology analysis.Statistical analysis was performed by using ฀ test, Student t test, Mann-Whitney U
test, and Barnard exact test. Results: Dextromethorphan was abused by 12 (11.5%) patients, 11 (91.7%)
of whom did not report concomitant abuse of dextromethorphan but were identified through hair anal-
ysis. In general, there were significant differences among patients abusing dextromethorphan compared
with nondextromethorphan consumers in terms of trauma due to sexual maltreatment/violence, multiple
traumas, or harmful use of hallucinogenic drugs. Conclusions: Further studies are necessary to examine
dextromethorphan and its impact on patients with psychiatric comorbidities and psychiatric medication.
According to literature, there is a significant drug interaction risk due to the impact of dextromethor-
phan misuse on serotonin syndrome and psychiatric symptoms. We recommend active inquiry into and
testing for concomitant drug abuse among substituted opioid-dependent patients to reduce the risk of
drug interactions and side effects in this especially vulnerable group of patients.
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Dextromethorphan Abuse Among Opioid-Dependent
Patients
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Background: Among opioid-dependent patients on maintenance ther-
apy, concomitant drug abuse is a serious problem. Dextromethorphan, an
over-the-counter antitussive agent that can be purchased without prescrip-
tion, is a drug with a high potential for misuse, especially when consumed
in high doses.
The objective of this study was to investigate possible abuse of dex-
tromethorphan among substituted opioid-dependent patients and compari-
son of subjective and objective findings.
Due to its ability to increase serotonin levels, opioid-dependent pa-
tients may be particularly susceptible to dextromethorphanmisuse. Dextro-
methorphan misuse may have side effects, including psychiatric symptoms
and serotonin syndrome, and may induce assault, suicide, or homicide.
Methods: A total of 104 opioid-dependent patients in maintenance treat-
ment were included in this cross-sectional study conducted in the outpa-
tient department of the Psychiatric Hospital, University of Zurich. Study
participants were divided into 2 groups based on laboratory results: dextro-
methorphan abusers (n = 12) and nonabusers (n = 92). The objective use
and concentrations of dextromethorphan was detected using 3-month hair
toxicology analysis.
Statistical analysis was performed by using χ2 test, Student t test,
Mann-Whitney U test, and Barnard exact test.
Results: Dextromethorphan was abused by 12 (11.5%) patients, 11 (91.7%)
of whom did not report concomitant abuse of dextromethorphan but were
identified through hair analysis. In general, there were significant differences
among patients abusing dextromethorphan comparedwith nondextromethorphan
consumers in terms of trauma due to sexual maltreatment/violence, multiple
traumas, or harmful use of hallucinogenic drugs.
Conclusions: Further studies are necessary to examine dextromethor-
phan and its impact on patients with psychiatric comorbidities and psychi-
atric medication. According to literature, there is a significant drug interaction
risk due to the impact of dextromethorphan misuse on serotonin syndrome
and psychiatric symptoms.1–3 We recommend active inquiry into and test-
ing for concomitant drug abuse among substituted opioid-dependent pa-
tients to reduce the risk of drug interactions and side effects in this
especially vulnerable group of patients.
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D extromethorphan, an N-methyl-D-aspartate (NMDA) antago-nist and sigma-1 receptor agonist, is an antitussive agent that
has been available as an over-the-counter medication in pharma-
cies without a prescription since 1954. There has been an alarming
increase in reports of its abuse cases (7- to 10-fold between 1999
and 2004),4mainly among young people taking dextromethorphan
as a psychoactive drug (tripled from 2000 to 2006 and plateaued
from 2006 to 2015).5
However, current data are incomplete regarding the extent of
the problem and its significance in addiction medicine.6
Due to its NMDA receptor agonism and sigma-1 receptor an-
tagonism, the pharmacodynamic effects of dextromethorphan are
similar to lysergic acid diethylamide, psilocybin or ketamine.7,8
Consequently, dextromethorphan is a member of the group of sub-
stances with psychoactive (dissociative) effects. As its chemical
structure is similar to that of codeine, dextromethorphan was clas-
sified as a synthetic opioid until recently. Because the sigma-1
receptor is no longer considered an opioid receptor, nowadays,
dextromethorphan is accordingly no longer classified as an opi-
oid.7,9,10 The antitussive effect is likely mediated by both NMDA
and sigma-1 receptors.11 Gamma-aminobutyric acid (GABA)-ergic/
antiglutamatergic mechanisms play an important role in the
etiopathogenesis of addictive behavior and in the development
of dependency.12Occasional substance use behavior often develops
over time into uncontrolled, rigid, compulsive-repetitive conduct,
and the development of tolerance is accompanied by autonomic
withdrawal symptoms.13 In addition, many addictive substances re-
duce GABAergic neurotransmission and reinforce glutamatergic
neurotransmission (glutamatergic hyperexcitability), with excitatory
transmission provided by NMDA receptors (glutamate receptors).14
Soyka and colleagues showed that theNMDAantagonist dextrome-
thorphan, acting as a glutamate antagonist, shows addictive poten-
tial due to the development of psychotropic effects analogous to
those of alcohol.15
Taken at low doses, dextromethorphan rarely shows side ef-
fects, although itching, vertigo, fatigue, vomiting, and nausea are
occasionally observed.16 Taken together with monoamine oxidase
inhibitors, the antihistamine terfenadine or selective serotonin re-
uptake inhibitors, dextromethorphan has been linked to potentially
life-threatening interactions, such as serotonin syndrome.16–18
Dextromethorphan is predominantly metabolized in the liver
by cytochrome P450 2D6 (CYP2D6). Around 1% to 3% of the
German population are ultrarapid metabolizers, showing a high
CYP2D6 activity level, whereas 7% to 10% are poor metabolizers
who show no CYP2D6 activity.19 Many individuals, therefore,
have an extended plasma half-life of dextromethorphan that can
lead to psychoactive effects even at therapeutic doses.
Concomitant drug abuse is a serious issue, especially among
opioid-dependent patients in replacement therapy.1 Clinical and
epidemiological studies show that substance use disorders and
psychiatric disorders are highly comorbid,2 and psychiatric disor-
ders are often accompanied by diverse medications, such as selec-
tive serotonin reuptake inhibitors and others. Due to drug
interactions, substituted patients who use dextromethorphan
are, therefore, exposed to a higher risk of developing (addi-
tional) psychiatric symptoms or serotonin syndrome, because
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high doses of dextromethorphan can result in hallucinations and
mania.3 Dextromethorphan use may also result in homicide, sui-
cide, or assault, as reported in 5 cases.3
Dextromethorphan is nowadays marketed as a constituent of
a large number of generic drugs. Between 2007 and 2008, sales of
1 commercial preparation rose by 32.9% (measured in defined
daily dose) for unknown reasons.20
However, to date, there are no detailed epidemiological data
on dextromethorphan abuse as a psychoactive substance, although
at least 5 cases of confirmed dextromethorphan dependency have
been described in the literature so far.21
In this study, we investigated the proportion of study partici-
pantswho used dextromethorphan in addition to their replacement
therapy. Because of their concomitant drug abuse, the participants
illustrate a vulnerable group of patients due to drug interactions
and related side effects. We, therefore, checked for specificities
in their appearances and related behavioral patterns. Subjective pa-
tient statements were first collected with the help of questionnaires,
followed by a 3-month hair toxicology analysis that objectively deter-
mined the ingestion and concentrations of dextromethorphan.
MATERIALS AND METHODS
Subjects
Hair sampleswere originally analyzed in the context of a study
conducted in an outpatient setting at the Centre for Addictive Disor-
ders of the Psychiatric Hospital, University of Zurich in 2014.22,23
From that study, we analyzed in further detail a range of substances
TABLE 1. Patient Characteristics
Patient Characteristics DXM (n = 12) No DXM (n = 92) Total (N = 104) P
Sex, n (%) 0.221*
Male 7 (58.3) 69 (75) 76 (73.1) 0.254†
Female 5 (41.7) 23 (25) 28 (26.9)
Age (mean ± SD) 37.6 ± 6.9 41.63 ± 8.7 41.16 ± 8.6 0.125‡
School, n (%) 0.466*
None 1 (8.3) 3 (3.3) 4 (3.8)
Middle school 4 (33.3) 30 (32.6) 34 (32.7)
High school 7 (58.3) 46 (50) 53 (51)
Academic high school 0 (0) 13 (14.1) 13 (12.5)
Education, n (%) 0.407*
None 5 (41.7) 20 (21.7) 25 (24)
Apprenticeship 7 (58.3) 65 (70.7) 72 (69.2)
University of applied science 0 (0) 5 (5.4) 5 (5.4)
University 0 (0) 2 (2.2) 2 (2.2)
Employed, n (%) 0.344*
Full-time 0 (0) 7 (7.6) 7 (6.7)
Part-time 0 (0) 7 (7.6) 7 (6.7)
Unemployed 0 (0) 10 (10.9) 10 (9.6)
Disability 7 (58.3) 51 (55.4) 58 (55.8)
Student 0 (0) 1 (1.1) 1 (1)
Certified sick 1 (8.3) 4 (4.3) 5 (4.8)
Other 4 (33.3) 10 (10.9) 14 (13.5)
Not classified 0 (0) 2 (2.2) 2 (1.9)
No. psychiatric comorbidities (mean ± SD) 1.58 ± 0.99 1.61 ± 1.16 1.61 ± 1.14 0.942‡
No. clinical treatments (mean ± SD) 5.5 ± 7.66 6.52 ± 7.61 6.40 ± 7.58 0.662‡
BDI (mean ± SD) 18.08 ± 8.21 16.15 ± 9.19 16.38 ± 9.06 0.491‡
HIV, n (%) 0.971*
Yes 1 (8.3) 6 (6.52) 7 (6.73) 0.962†
No 9 (75) 71 (77.17) 80 (76.92)
Unknown 2 (16.66) 15 (16.3) 17 (16.35)
Hepatitis C, n (%) 0.204*
Yes 7 (58.33) 36 (39.13) 43 (41.35) 0.217†
No 5 (41.66) 56 (60.87) 61 (58.65)
Serotonergic medication (fluoxetin, citalopram, trimipramin) 0.645*
Yes 3 (25) 29 (31.52) 32 (30.77) 0.836†
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in 104 patients, including 76 male and 28 female participants, in
opioid substitution therapy.
All 104 patients were included in this cross-sectional study,
including 12 with comorbid dextromethorphan use and 92 patients
with no dextromethorphan use.
The inclusion criteria were a diagnosis of opioid dependence
according to Diagnostic and Statistical Manual of Mental Disor-
ders IV criteria and participation in opioid substitution therapy
at the time of the study. Insufficient command of the German lan-
guage or younger than 18 years and older than 65 years were ex-
clusion criteria. Neither prescribed comedication nor psychiatric
comorbidities were excluded.
All participants gave written informed consent before partic-
ipation in the study and received a payment of 5 Swiss Francs. The
ethics committee of the canton of Zurich approved the study protocol.
Study Design
The participants were divided into 2 groups on the basis of
laboratory hair toxicology analysis of dextromethorphan abuse
(n = 12; including 7 male and 5 female participants) or no dextro-
methorphan consumption (n = 92; including 69 male and 23
female participants).
The Institute of Forensic Medicine at the University of
Zurich evaluated drug use based on a 3-month hair toxicology
analysis that quantifies the concentration of the substances or their
metabolites. This analysis also revealed the fraction of hair sam-
ples in which dextromethorphan was represented.
With the help of electronic medical records, data were col-
lected on psychiatric diagnoses based on ICD-10. Demographic
data, such as sex, age, years and type of education, employment
status, as well as the number of clinical treatments, were obtained
by self-reporting via questionnaires.
Craving was assessed using the visual analog scale, ranging
from 1 to 100 (Rosenberg, 2009).24 Depression and anxiety were
analyzed with help of the Beck Depression Inventory (BDI)25 and
the State-Trait Anxiety Inventory26 (Beck et al., 1961; Spielberger
et al., 1983).
Study Assessment
The outcome of the study was a comparison of the subjective
reporting of dextromethorphan abuse to objective hair concentra-
tions of dextromethorphan found in substituted opioid-dependent
patients. Concentrations of dextromethorphan in hair samples were
tested and quantified by 3-month hair toxicology analysis using liq-
uid chromatography-tandem mass spectrometry. Concentrations
lower than 60 pg/mg were considered negligible because they
do not represent abusive consumption of dextromethorphan, which
led to 3 of 15 patients being regarded as unremarkable dextrome-
thorphan users.27 The remaining 12 patients were classified as
dextromethorphan abusers due to a concentration greater than
60 pg/mg dextromethorphan in their hair samples.
Hair Analysis
A 3-month hair toxicology analysis, carried out at the Insti-
tute of Forensic Medicine at the University of Zurich, was used
for assessing abusive dextromethorphan consumption. Using head
hair, the proximal 3-cm section of the collected head hair locks
was investigated. Whenever little or no, or only heavily bleached
TABLE 2. Subjective and Objective Findings
Group Characteristics DXM (n = 12) No DXM (n = 92) Total (N = 104) P
Dextromethorphan subjective, n (%) 0.005*
Yes 1 (8.33) 0 (0) 1 (0.96) 0.047†
No 11 (91.67) 92 (100) 103 (99.04)
Dextromethorphan objective, n (%) 0.000*
Yes 12 (100) 0 (0) 12 (11.54) 0.000†
No 0 (0) 92 (100) 92 (88.46)
Cocaine subjective, n (%) 0.277*
Yes 9 (75) 54 (58.69) 63 (60.58) 0.318†
No 3 (25) 38 (4.30) 41 (39.42)
Cocaine objective, n (%) 0.277*
Yes 9 (75) 54 (58.69) 63 (60.58) 0.318†
No 3 (75) 38 (4.30) 41 (39.42)
Heroine subjective, n (%) 0.751*
Yes 5 (41.67) 34 (36.96) 39 (37.5) 0.943†
No 7 (58.33) 58 (63.04) 65 (62.5)
Heroine objective, n (%) 0.646*
Yes 4 (33.33) 37 (40.22) 41 (39.42) 0.836†
No 8 (66.67) 55 (59.78) 63 (60.58)
Methylphenidate subjective, n (%) 0.069*
Yes 6 (50) 23 (25) 29 (27.88) 0.072†
No 6 (50) 69 (75) 75 (72.12)
Methylphenidate objective, n (%) 0.776*
Yes 6 (50) 50 (54.35) 56 (53.85) 0.943†
No 6 (50) 42 (45.65) 48 (46.15)
*Pearson χ2 test.
†Barnard exact test.
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hair was available, body hair was used. Assuming an average growth
rate of 1 cm/month, the hair segment represents the consumption
behavior of the last 3 months before collection.23 The analytical
limits of the method enable the detection of very low concentra-
tion in the hair samples. However, strong cosmetic treatments like
bleaching can degrade the incorporated substances.28 Hair sam-
ples were analyzed according to Rust et al.29 In brief, the hair sam-
ple was washed in water, acetone, and hexane for 2 minutes each.
Then dried at room temperature, cut into small snippets, and ex-
tracted in methanol (extraction step 1) and a mixture of methanol
and ammonium formate buffer (extraction step 2) for 90 minutes
each. After each extraction step, the organic layers were separated
by centrifugation and dried under a stream of nitrogen at 36°C. Fi-
nally, the residues were combined, redissolved in methanol and
aqueous ammonium format buffer solution, and then the samples
were analyzedwith liquid chromatography-tandemmass spectrometry.23
Statistical Analysis
General Aspects of Applied Statistical Methods
Data analysis was performed using Excel for Mac, version
15.29. The χ2 test was used for categorical variables and Student
t test for continuous variables. Differences in baseline characteris-
tics between the 2 groups were compared. The Mann-Whitney U
test was used to identify nonparametric variables to compare
quantitative dextromethorphan use between the 2 groups.30
The results of the hair analysis were recoded to count the per-
centages of study participants with dextromethorphan use. All
values of 0 were classified as no, and all values greater than 0 were
classified as yes. With the help of the χ2 test the 2 groups were
compared, and the null hypothesis (X and Y characteristics are in-
dependent) confirmed or rejected.
Accordingly, we considered P values less than 0.05 as statis-
tically significant and conditional for rejecting the null hypothesis
and thus confirming a dependency of the X and Y characteristics.
Weakness of the χ2 independence test
Theχ2 goodness of fit test is appropriate when the following
conditions are met: (1) the sampling method is simple random
sampling, (2) the variable under study is categorical, and (3) the
expected value of the number of sample observations for each var-
iable is at least 5.
The data in this study only partially fulfill condition 3 because
although the group of comorbid dextromethorphan abuse patients
counted 12 subjects, certain subgroups with side effects such as
psychiatric symptoms, serotonin syndrome, assault, suicide,
or homicide often consisted of fewer than 5 subjects.
Accordingly, we also used exact statistical methods of rele-
vance for smaller sample numbers.
Exact Statistical Tests for Independence
There are 2 fundamentally different exact tests for comparing
the equality of 2 binomial probabilities—Fisher exact test (Fisher,
1925),31 and Barnard exact test (Barnard, 1945).32,33 Fisher exact
test is the more popular of the 2. The main difference between the
Fisher and Barnard tests is the manner in which they eliminate a
nuisance parameter π from a test statistic measuring how discrep-
ant any Table X is relative to the type of table that would be ex-
pected under the null hypothesis, without sacrificing exactness.
To eliminate the unknown nuisance parameter π in theP value
calculation, Barnard suggested calculating p (π) for all possible
values of π ∈ (0, 1) and choosing the value, π*, that maximizes
p (π). This “Barnard P value” pB is smaller than that generated by
TABLE 3. Psychiatric Comorbidity: Traumas
Patient Characteristics DXM (n = 12) No DXM (n = 92) Total (N = 104) P
Simple PTSD, n (%) 0.685*
Yes 1 (8.33) 5 (5.43) 6 (5.77) 0.881†
No 11 (91.67) 87 (94.57) 98 (94.23)
Complex PTSD, n (%) 0.268*
Yes 3 (25) 12 (13.04) 15 (14.42) 0.317†
No 9 (75) 80 (86.96) 89 (85.58)
Trauma neglect, n (%) 0.788*
Yes 1 (8.33) 10 (10.87) 11 (10.58) 0.963†
No 11 (91.67) 82 (89.13) 93 (89.42)
Trauma sexual abuse, n (%) 0.39*
Yes 1 (8.33) 3 (3.26) 4 (3.85) 0.49†
No 11 (91.67) 89 (96.74) 100 (96.15)
Trauma sexual maltreatment/violence, n (%) 0.014*
Yes 2 (16.67) 2 (2.17) 4 (3.85) 0.0485†
No 10 (83.33) 90 (97.82) 100 (96.15)
Trauma violence, n (%) 0.294*
Yes 2 (16.67) 7 (7.61) 9 (8.65) 0.369†
No 10 (83.33) 85 (92.39) 95 (91.35)
Multiple traumas, n (%) 0.032*
Yes 3 (25) 6 (6.52) 9 (8.65) 0.0485†
No 9 (75) 86 (93.48) 95 (91.35)
*Pearson χ2 test.
†Barnard exact test.
PTSD, posttraumatic stress disorder.
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Fisher exact test (pF), and thus suggests that Barnard test is more
powerful than Fisher. This is a direct consequence of restricting
Fisher test to 2  2 tables belonging to a conditional reference,
rather than Barnard larger unconditional reference set and mirrors
the much more discrete sample space for Fisher exact test than for
Barnard exact test.
When finally comparing Fisher and Barnard exact tests, the
loss of power due to the greater discreteness of the Fisher statistic
is somewhat offset by the requirement that Barnard exact test must
maximize over all possible P values, by choice of the nuisance pa-
rameter π. For 2  2 tables, the loss of power due to discreteness
dominates over the loss of power due tomaximization, resulting in
greater power for Barnard exact test. For details, see also Mehta
and Hilton.34
Accordingly, we decided to apply Barnard exact test to prove
or reject our null hypothesis of XY independency and compare the
results to those of the χ2 test (see Tables 1-4, for included 2  2
matrices).
RESULTS
Of the 104 study participants, 76 (73.1%) were male and 28
(26.9%) were female, with a mean (±SD) age of 41.16 years
(±8.6 years). Two groups were studied; dextromethorphan abusers
(n = 12) and nondextromethorphan consumers (n = 92). Table 1
shows detailed patient characteristics. There were no significant
differences between these 2 groups in terms of sex, type, and years
of education, employment status, number of psychiatric comor-
bidities, BDI score, number of inpatient treatments, HIV status,
hepatitis C or serotonergic medication.
Among the participants, 12 (11.5%) patients were identified
as dextromethorphan abusers through hair analysis. Of this group,
11 (91.7%) patients failed to report abuse of dextromethorphan.
Detailed patient statements are shown in Table 2. For all 12 of the
dextromethorphan abusers who additionally consumed cocaine,
heroin, and methylphenidate, this additional abuse was reported.
Three (25%) participants abusing dextromethorphan additionally
took serotonergic medication, such as fluoxetine, citalopram,
or trimipramin. Furthermore, patients were examined regarding
psychiatric comorbidities, such as posttraumatic stress disorder and
various types of traumas.
As shown in Table 3, we also identified a related statistically
significant relationship between (a) trauma due to sexual maltreatment/
violence and (b) multiple traumas, and dextromethorphan abuse.
In addition, a similarly significant (5% level) dependency was
identified for the harmful use of hallucinogens for 1 person within
the group of dextromethorphan abusers, as illustrated in Table 4 and
confirmed by both statistical tests.
DISCUSSION
Patients on maintenance therapy generally have multiple as-
sociated psychiatric comorbidities,29,35,36 are often treated with
psychotropic drugs, and are frequently active drug abusers.37 This
type of patient group is, therefore, more exposed to the risk of
drug interactions that may then result in further psychiatric symp-
toms, serotonin syndrome, or even serious incidents, such as as-
saults, homicide, or suicide.2 With the help of clinical diagnoses,
we attempted to determine whether dextromethorphan abusers show
predictors or distinctive features. Regarding patient characteris-
tics, such as sex, type and years of education, employment status,
number of psychiatric comorbidities, BDI score and numbers of
inpatient treatments, HIV status and hepatitis C or types of trauma,
such as simple PTBS, complex PTBS, trauma through neglect,
trauma through sexual abuse and trauma through violence, there
were no statistically significant differences between dextromethor-
phan abusers and nondextromethorphan abusers. However, statisti-
cally significant differences were identified in relation to (1) trauma
through sexual maltreatment/violence, (2) multiple traumas, and (3)
the harmful use of hallucinogenic drugs among the dextromethor-
phan abuser group. To date, there are no indications in the literature
TABLE 4. ICD-10 Diagnosis
Patient Characteristics DXM (n = 12) No DXM (n = 92) Total (N = 104) P
F14.1 Use of cocaine, harmful use, n (%) 1*
Yes 3 (25) 23 (25) 26 (25) 1†
No 9 (75) 69 (75) 78 (75)
F14.2 Use of cocaine, dependence syndrome, n (%) 0.470*
Yes 6 (50) 36 (39.13) 42 (45.65) 0.608†
No 6 (50) 56 (60.87) 62 (59.62)
F15.1 Use of stimulants, harmful use, n (%) 0.362*
Yes 0 (0) 6 (6.52) 6 (5.77) 0.448†
No 12 (100) 86 (93.48) 98 (94.23)
F15.2 Use of stimulants, dependence syndrome, n (%) 0.382*
Yes 1 (8.33) 17 (18.48) 18 (17.31) 0.476†
No 11 (91.67) 75 (81.52) 86 (82.69)
F16.1 Use of hallucinogens, harmful use, n (%) 0.005*
Yes 1 (8.33) 0 (0) 1 (0.96) 0.047†
No 11 (91.67) 92 (100) 103 (99.04)
F16.2 Use of hallucinogens, dependence syndrome, n (%) 0.526*
Yes 0 (0) 3 (3.26) 3 (2.88) 0.682†
No 12 (100) 89 (96.74) 101 (97.12)
*Pearson χ2 test.
†Barnard exact test.
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for trauma due to sexual maltreatment/violence or multiple traumas
as possible predictors of dextromethorphan misuse.
Finally, we were not able to explain the discrepancy between
subjective statements and the proven abuse of dextromethorphan.
This was especially puzzling because these patients were aware
that admitting abuse would have no negative consequences. The
concealment of dextromethorphan consumption among opioid
abusers willing to admit concomitant cocaine, heroin and methyl-
phenidate consumption remains to be explained. It is hypothesized
that at the time of execution of the base study (2014), dextromethor-
phan was not identified by the members of the abusers group as a
relevant drug impacting on their status like, for example, compared
with heroin or cocaine, because dextromethorphan could be re-
ceived by over-the-counter sales.
CONCLUSION
We recommend active inquiry and testing for concomitant
dextromethorphan abuse among opioid-dependent patients to avoid
drug interactions and side effects in this especially vulnerable group
of patients. In this context, we also recommend further exploration
of (a) trauma due to sexual maltreatment/violence and (b) multiple
traumas as possible predictors of dextromethorphan misuse.
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11 of 12). This means that the patients in the abuser group applied
dextromethorphan as an antitussive agent due to its over-the-
counter purchase and did not report its use as a drug.
The abovementioned limitations would have only shifted the
ratio between objective and subjective identification results for the
abusers group but had not impacted on the statistical evaluation
of possibly correlated traumas.
The differentiation between use and abuse of dextromethor-
phan has been defined from the hair toxicology analysis as ad-
vised by the toxicological expert in charge.
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